Author
University of North Carolina at Chapel HillORCID 0000-0003-3392-2848Unclaimed ORCID profile · follow to get notified of new preprints
5 papers
Recent·Most cited
Raymond G. Flax, Andrea Lacigová, Stefanie Howell…·Alison Donnelly Axtman
This study develops and characterizes a potent and cell-active inhibitor of TTBK1 and TTBK2, with selectivity and potential therapeutic applications for neurodegenerative diseases.
Umar Mehraj, Uran Maimekov, Shaista Manzoor…·Everardo Macias
This paper identifies NUAK2 as a therapeutic target in AR-indifferent prostate cancer, showing trilaciclib inhibits NUAK2 and suppresses tumor growth.
Anirban Ghoshal, John D. Sears, Mohammad Anwar Hossain…·Timothy Mark Willson
Jacob L. Capener, James D. Vasta, Vittorio L. Katis…·Frances M. Bashore
The paper develops a NanoBRET assay to study SYK gain-of-function variants in live cells and demonstrates inhibitor efficacy against these variants.
Frances M. Bashore, Sophia M. Min, Xiangrong Chen…·Alison D. Axtman
The paper identifies and characterizes a chemical probe for CDKL2, demonstrating its selectivity and biological impact in neurons and cancer cells.